سعر نيريسيد فورت 0.3% مرهم 10جم 2022

Diflucortolone valerate 0.3% topical fatty ointment (10 g tube) by CID, Egypt; very potent short-term topical corticosteroid preparation.

• Problematic dermatoses such as psoriasis vulgaris, neurodermatitis (endogenous eczema, atopic dermatitis), lichen ruber planus and verrucosus, chronic discoid lupus erythematosus and severe chronic eczema.CID EXPORT product gallery (cid.do.am)

• With large areas (about 10% or more) and/or long use (more than 10 days): skin atrophy, telangiectasia, striae, acneiform changes, perioral dermatitis, hypertrichosis and systemic corticosteroid effects; rarely allergic skin reactions.Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Common local reactions: burning, pruritus, erythema and irritation. With large areas (10% or more) or long use (more than 4 weeks), especially with occlusion: skin atrophy, telangiectasia, striae, acneiform changes, perioral dermatitis, hypertrichosis and systemic corticosteroid effects; rarely allergic skin reactions.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Tuberculous or syphilitic processes in the treated area; viral diseases (e.g. vaccinia, smallpox, chickenpox); infants and children up to 4 years; application to the face; acne vulgaris, undiagnosed perianal and genital pruritus, napkin rash, primary bacterial or fungal skin infections; secondary infections without anti-infective therapy; ophthalmic conditions. Large amounts or prolonged use should be avoided in the first trimester of pregnancy.Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Rosacea and perioral dermatitis; acne vulgaris; undiagnosed perianal and genital pruritus; napkin eruptions; viral infections; primary bacterial or fungal skin infections; secondary infections without appropriate anti-infective therapy; post-vaccination skin reactions in the treated area; ophthalmic conditions; hypersensitivity to the active substance or excipients.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Bacterial and/or fungal skin infections need additional specific therapy; occlusive dressings should not be left on for more than 24 hours and should be stopped if secondary infection occurs; careful supervision in psoriasis (rebound relapse, generalised pustular psoriasis, toxicity).Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Adrenal suppression can occur even without occlusion; systemic absorption increases with occlusion, large areas or prolonged use.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)
• Use in psoriasis may be hazardous (rebound relapse, generalised pustular psoriasis, local and systemic toxicity); careful supervision is needed.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Inadequate evidence of safety in human pregnancy; topical corticosteroids in pregnant animals can cause foetal abnormalities (e.g. cleft palate, intra-uterine growth retardation); application to large areas or for prolonged periods must be avoided.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)
• Side effects in neonates cannot be excluded after extensive or prolonged maternal use during pregnancy or lactation; nursing mothers should not apply it to the breasts.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Diflucortolone valerate: Suppresses cutaneous inflammation and alleviates pruritus/burning in inflammatory dermatoses.